Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Chevalier B, Smits P, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Wasungu L, Ediebah D, Veldhof S, Onuma Y. Serruys PW, et al. Among authors: ediebah d. J Am Coll Cardiol. 2016 Feb 23;67(7):766-76. doi: 10.1016/j.jacc.2015.11.060. J Am Coll Cardiol. 2016. PMID: 26892411 Free article. Clinical Trial.
Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial.
Costa JR Jr, Abizaid A, Whitbourn R, Serruys PW, Jepson N, Steinwender C, Stuteville M, Ediebah D, Sudhir K, Bartorelli AL; ABSORB EXTEND investigators. Costa JR Jr, et al. Among authors: ediebah d. Catheter Cardiovasc Interv. 2019 Jan 1;93(1):E1-E7. doi: 10.1002/ccd.27715. Epub 2018 Oct 4. Catheter Cardiovasc Interv. 2019. PMID: 30286520 Clinical Trial.
One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials.
de Ribamar Costa J Jr, Abizaid A, Bartorelli AL, Whitbourn R, Jepson N, Perin M, Steinwender C, Stuteville M, Ediebah D, Sudhir K, Serruys PW. de Ribamar Costa J Jr, et al. Among authors: ediebah d. EuroIntervention. 2016 Nov 20;12(10):1255-1262. doi: 10.4244/EIJV12I10A206. EuroIntervention. 2016. PMID: 27866134 Free article. Clinical Trial.
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, Tan SH, Ediebah DE, Simonton C, Stone GW; ABSORB III Investigators. Kereiakes DJ, et al. Among authors: ediebah de. Circulation. 2019 Dec 3;140(23):1895-1903. doi: 10.1161/CIRCULATIONAHA.119.042584. Epub 2019 Sep 25. Circulation. 2019. PMID: 31553222
Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
Kozuma K, Tanabe K, Hamazaki Y, Okamura T, Ando J, Ikari Y, Nakagawa Y, Kusano H, Ediebah D, Kimura T; ABSORB Japan Investigators. Kozuma K, et al. Among authors: ediebah d. Circ J. 2020 Apr 24;84(5):733-741. doi: 10.1253/circj.CJ-19-1184. Epub 2020 Mar 26. Circ J. 2020. PMID: 32213737 Free article. Clinical Trial.
Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
Ediebah DE, Quinten C, Coens C, Ringash J, Dancey J, Zikos E, Gotay C, Brundage M, Tu D, Flechtner HH, Greimel E, Reeve BB, Taphoorn M, Reijneveld J, Dirven L, Bottomley A; Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer. Ediebah DE, et al. Cancer. 2018 Aug;124(16):3409-3416. doi: 10.1002/cncr.31556. Epub 2018 Jun 15. Cancer. 2018. PMID: 29905936 Free article.
A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.
Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, Bjordal K, Greimel E, Reeve BB, Maringwa J, Ediebah DE, Zikos E, King MT, Osoba D, Taphoorn MJ, Flechtner H, Schmucker-Von Koch J, Weis J, Bottomley A; Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups. Quinten C, et al. Among authors: ediebah de. Cancer. 2014 Jan 15;120(2):302-11. doi: 10.1002/cncr.28382. Epub 2013 Oct 11. Cancer. 2014. PMID: 24127333 Free article.
17 results